APM
CRNX icon

Avidity Partners Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Avidity Partners Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-529,000
Closed -$18.8M – 99
2023
Q4 		$18.8M Sell
529,000
-81,000
-13% -$2.48M 0.69% 50
2023
Q3 		$18.1M Buy
+610,000
New +$12.6M 0.73% 51

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Avidity Partners Management's CRNX Position: Q1 2024 in Review

Avidity Partners Management sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2024, closing a stake of 529,000 shares — an estimated $18.8M sold.

Avidity Partners Management first reported a position in CRNX in Q3 2023 and held it in 2 quarters. The position peaked at $18.8M in Q4 2023. 203 funds tracked by Wall St. Rank hold CRNX as of Q1 2024.

  • Avidity Partners Management reported no remaining Crinetics Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Avidity Partners Management sold 529,000 Crinetics Pharmaceuticals shares in Q1 2024, an estimated $18.8M.
  • Avidity Partners Management first reported a position in Crinetics Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Avidity Partners Management's Crinetics Pharmaceuticals position peaked at $18.8M in Q4 2023.
  • 203 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2024.

Based on Avidity Partners Management's 13F filing for Q1 2024, filed 15 May 2024.